tiprankstipranks
Trending News
More News >
Replicel (REPCF)
:REPCF
Advertisement

RepliCel Life Sciences (REPCF) Price & Analysis

Compare
22 Followers

REPCF Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

30.78%69.22%
30.78% Insiders
― Other Institutional Investors
69.22% Public Companies and
Individual Investors

REPCF FAQ

What was Replicel’s price range in the past 12 months?
Replicel lowest stock price was $0.01 and its highest was $0.04 in the past 12 months.
    What is Replicel’s market cap?
    Replicel’s market cap is $766.80K.
      When is Replicel’s upcoming earnings report date?
      Replicel’s upcoming earnings report date is Sep 01, 2025 which is in 36 days.
        How were Replicel’s earnings last quarter?
        Currently, no data Available
        Is Replicel overvalued?
        According to Wall Street analysts Replicel’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Replicel pay dividends?
          Replicel does not currently pay dividends.
          What is Replicel’s EPS estimate?
          Replicel’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Replicel have?
          Replicel has 70,003,020 shares outstanding.
            What happened to Replicel’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Replicel?
            Currently, no hedge funds are holding shares in REPCF

            Company Description

            Replicel

            RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
            Similar Stocks
            Company
            Price & Change
            Follow
            Knight Therapeutics
            Resverlogix
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis